| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Chief Development Officer | Interim Chief Operating Office
3 companies
Wendy S. Johnson last filed a Form 4 in June 2023, as Director at XGN. The filings on record cover 3 companies. Wendy S. Johnson's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 1,000 shares of XGN. Net of sales, the XGN filings show accumulation of 1,000 shares.
Wendy S. Johnson has 11 Form 4 filings on record from September 2015 to June 2023, across 3 companies: Director at Exagen (XGN), 2020–2023; Chief Development Officer at OnKure Therapeutics (OKUR), 2021; Director at Armata Pharmaceuticals (ARMP), 2015–2017.
The 11 reported transactions were 7 option or other derivative awards, 2 open-market purchases, 1 open-market sale and 1 option exercise.
Counted by filing, the open-market trades come to 2 purchases worth about $18K and 1 sale worth about $950K.
The largest open-market purchase was 1,000 shares of XGN at an average $14.02 on September 3, 2021, about $14K. Twelve months later XGN was down 67%.
The only open-market sale was 111,736 shares of OKUR at an average $8.50 on July 14, 2021, about $950K. Twelve months later OKUR was down 65%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2021 | XGN Exagen Inc. | Director | Buy | 1,000 | $14.02 | $14,020.00 | New | -26.4% | -67.0% | |
| Jul 14, 2021 | OKUR Onkure Therapeutics, Inc. | Chief Development Officer | Sell | 111,736 | $8.50 | $949,756.00 | -100% | -22.3% | -65.2% | |
| Oct 5, 2015 | ARMP Armata Pharmaceuticals, Inc. | Interim Chief Operating Office | Buy | 1,000 | $4.43 | $4,427.00 | New | - | - |